MEF2C and acute lymphoblastic leukemia: We tested if high expression levels of MEF2C were directly associated with PSL resistance in T-ALL cells because MEF2C may augment BCL2 activity to inhibit apoptosis [19], and be responsible for the poor responsiveness to the initial treatment of T-ALL with PSL.